CD274 and neoplasm: KEYNOTE-028 multicohort phase 1b trail study: Pembrolizumab (mAb against PD-L1) monotherapy in patients with recurrent or metastatic NPC. Pembrolizumab had promising anti-tumor activity and a manageable safety profile.